{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:47:25Z","timestamp":1779364045463,"version":"3.53.0"},"reference-count":156,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.pharmthera.2013.07.009","type":"journal-article","created":{"date-parts":[[2013,7,21]],"date-time":"2013-07-21T03:21:04Z","timestamp":1374376864000},"page":"306-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions"],"prefix":"10.1016","volume":"140","author":[{"given":"Danielle","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Jon","family":"Stoessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2013.07.009_bb0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2008.03.016","article-title":"Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders","volume":"102","author":"Agid","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S1474-4422(11)70101-6","article-title":"Cell therapy for Parkinson's disease: have the glory days gone?","volume":"10","author":"Albanese","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","article-title":"Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health","volume":"4","author":"Allen","year":"2003","journal-title":"Sleep Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0020","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1523\/JNEUROSCI.19-01-00484.1999","article-title":"Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems","volume":"19","author":"Amanzio","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0030","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1017\/S1041610211002420","article-title":"A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment","volume":"24","author":"Amanzio","year":"2012","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0304-3959(00)00486-3","article-title":"Response variability to analgesics: a role for non-specific activation of endogenous opioids","volume":"90","author":"Amanzio","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0035","doi-asserted-by":"crossref","first-page":"8053","DOI":"10.1523\/JNEUROSCI.0383-12.2012","article-title":"Dissociable influences of opiates and expectations on pain","volume":"32","author":"Atlas","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10194-012-0422-0","article-title":"Placebo and other psychological interactions in headache treatment","volume":"13","author":"Autret","year":"2012","journal-title":"J Headache Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.yebeh.2010.12.005","article-title":"An estimate of placebo effect of repetitive transcranial magnetic stimulation in epilepsy","volume":"20","author":"Bae","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0055","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0304-3959(95)00179-4","article-title":"The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia","volume":"64","author":"Benedetti","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.pharmtox.48.113006.094711","article-title":"Mechanisms of placebo and placebo-related effects across diseases and treatments","volume":"48","author":"Benedetti","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0065","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.pain.2012.06.007","article-title":"Placebo responses in animals","volume":"153","author":"Benedetti","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb9005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0301-0082(97)00006-3","article-title":"The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin","volume":"52","author":"Benedetti","year":"1997","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0105","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/nm.2435","article-title":"Non-opioid placebo analgesia is mediated by CB1 cannabinoid receptors","volume":"17","author":"Benedetti","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/npp.2010.81","article-title":"How placebos change the patient's brain","volume":"36","author":"Benedetti","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0085","doi-asserted-by":"crossref","first-page":"12014","DOI":"10.1523\/JNEUROSCI.2947-06.2006","article-title":"The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect","volume":"26","author":"Benedetti","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pain.2005.12.016","article-title":"Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective","volume":"121","author":"Benedetti","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0075","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nn1250","article-title":"Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus","volume":"7","author":"Benedetti","year":"2004","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0100","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1113\/jphysiol.2009.169425","article-title":"Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response","volume":"587","author":"Benedetti","year":"2009","journal-title":"J Physiol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0095","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuroscience.2007.02.020","article-title":"When words are painful: unraveling the mechanisms of the nocebo effect","volume":"147","author":"Benedetti","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0080","doi-asserted-by":"crossref","first-page":"10390","DOI":"10.1523\/JNEUROSCI.3458-05.2005","article-title":"Neurobiological mechanisms of the placebo effect","volume":"25","author":"Benedetti","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0070","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1523\/JNEUROSCI.23-10-04315.2003","article-title":"Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo\/nocebo responses","volume":"23","author":"Benedetti","year":"2003","journal-title":"J Neurosci"},{"issue":"70ra14","key":"10.1016\/j.pharmthera.2013.07.009_bb0115","first-page":"1","article-title":"The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil","volume":"3","author":"Bingel","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0120","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1001\/jama.2011.1850","article-title":"Lessons from recent research about the placebo effect \u2014 from art to science","volume":"306","author":"Brody","year":"2011","journal-title":"J Am Med Assoc"},{"issue":"e41929","key":"10.1016\/j.pharmthera.2013.07.009_bb0125","first-page":"1","article-title":"Shared \u201ccore\u201d areas between the pain and other task-related networks","volume":"7","author":"Cauda","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0130","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1526-4637.2012.01340.x","article-title":"Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis","volume":"13","author":"Cepeda","year":"2012","journal-title":"Pain Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0140","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1474-4422(12)70277-6","article-title":"Sham neurosurgical procedures: the patient's perspective","volume":"11","author":"Cohen","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0135","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1185\/03007991003604018","article-title":"PRISMS: the story of a pivotal clinical trial series in multiple sclerosis","volume":"26","author":"Cohen","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0145","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nrn1705","article-title":"Placebos and painkillers: is mind as real as matter?","volume":"6","author":"Colloca","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0150","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jama.2012.115","article-title":"Nocebo effects, patient\u2013clinician communication, and therapeutic outcomes","volume":"307","author":"Colloca","year":"2012","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0160","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.pain.2010.08.007","article-title":"How the number of learning trials affects placebo and nocebo responses","volume":"151","author":"Colloca","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.pain.2008.02.006","article-title":"The role of learning in nocebo and placebo effects","volume":"136","author":"Colloca","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0165","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/mds.24062","article-title":"Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease","volume":"27","author":"Cubo","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0170","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/cncr.24751","article-title":"Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer","volume":"116","author":"de la Cruz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0180","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/S1353-8020(09)70785-0","article-title":"The placebo-reward hypothesis: dopamine and the placebo effect","volume":"15S3","author":"de la Fuente-Fern\u00e1ndez","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0185","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1468-1331.2012.03719.x","article-title":"The powerful pre-treatment effect: placebo responses in restless legs syndrome trials","volume":"19","author":"de la Fuente-Fern\u00e1ndez","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0200","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0166-4328(02)00130-4","article-title":"Dopamine release in human ventral striatum and expectation of reward","volume":"136","author":"de la Fuente-Fern\u00e1ndez","year":"2002","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0195","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1126\/science.1060937","article-title":"Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease","volume":"293","author":"de la Fuente-Fern\u00e1ndez","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0205","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biopsych.2003.11.019","article-title":"Placebo mechanisms and reward circuitry: clues from Parkinson's disease","volume":"56","author":"de la Fuente-Fern\u00e1ndez","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0210","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1212\/01.wnl.0000324635.49971.3d","article-title":"The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies","volume":"71","author":"Diederich","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0215","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0924-977X(01)00084-0","article-title":"Placebo affects the performance of rats in models of depression: is it a good control for behavioral experiments?","volume":"11","author":"Drago","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0220","first-page":"114","article-title":"Placebo effects in neurological diseases","volume":"3","author":"Dumitriu","year":"2010","journal-title":"J Med Life"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0225","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.1180142","article-title":"Direct evidence for spinal cord involvement in placebo analgesia","volume":"326","author":"Eippert","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0230","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.pain.2011.10.036","article-title":"Neural mechanisms mediating the effects of expectation in visceral placebo analgesia: an fMRI study in healthy placebo responders and nonresponders","volume":"153","author":"Elsenbruch","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuron.2008.06.030","article-title":"New insights into the placebo and nocebo responses","volume":"59","author":"Enck","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0240","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3923","article-title":"The placebo response in medicine: minimize, maximize or personalize?","volume":"12","author":"Enck","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0245","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.euroneuro.2008.03.002","article-title":"Imaging the placebo response: a neurofunctional review","volume":"18","author":"Faria","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0250","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/WNL.57.4.613","article-title":"A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease","volume":"57","author":"Feldman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0255","series-title":"Wall and Melzack's Textbook of Pain","first-page":"125","article-title":"Central nervous system mechanisms of pain modulation","author":"Fields","year":"2006"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pain.2004.12.012","article-title":"Mechanisms of the placebo response and their impact on clinical trials and clinical practice","volume":"114","author":"Finniss","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0265","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0140-6736(09)61706-2","article-title":"Biological, clinical, and ethical advances of placebo effects","volume":"375","author":"Finniss","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0270","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1126\/science.1077349","article-title":"Discrete coding of reward probability and uncertainty by dopamine neurons","volume":"299","author":"Fiorillo","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0280","first-page":"54","article-title":"Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries","volume":"11","author":"Fricchione","year":"2005","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0285","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/brain\/awm244","article-title":"Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies","volume":"131","author":"Fulda","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0290","doi-asserted-by":"crossref","first-page":"13066","DOI":"10.1523\/JNEUROSCI.2534-08.2008","article-title":"A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety","volume":"28","author":"Furmark","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0295","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1474-4422(12)70064-9","article-title":"Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations","volume":"11","author":"Galpern","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0300","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0320","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mds.21897","article-title":"Placebo influences on dyskinesia in Parkinson's disease","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0305","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/mds.21894","article-title":"Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0325","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/archpsyc.61.1.34","article-title":"Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy","volume":"61","author":"Goldapple","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"70ps5","key":"10.1016\/j.pharmthera.2013.07.009_bb0330","first-page":"1","article-title":"For placebo effects in medicine, seeing is believing","volume":"3","author":"Gollub","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0335","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1474-4422(11)70097-7","article-title":"Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial","volume":"10","author":"Gross","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0340","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yebeh.2009.10.007","article-title":"Placebo responses in randomized trials of antiepileptic drugs","volume":"17","author":"Guekht","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0345","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00213-011-2259-7","article-title":"Placebo analgesia affects the behavioral despair tests and hormonal secretions in mice","volume":"21","author":"Guo","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0350","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.pain.2012.08.008","article-title":"Brain networks predicting placebo analgesia in a clinical trial for chronic back pain","volume":"153","author":"Hashmi","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0355","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.pain.2011.01.050","article-title":"Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy \u2014 magnitude and patient-related predictors","volume":"152","author":"H\u00e4user","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0360","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1353\/pbm.2005.0054","article-title":"Pain and the placebo: what we have learned","volume":"48","author":"Hoffman","year":"2005","journal-title":"Perspect Biol Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0365","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200105243442106","article-title":"Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment","volume":"344","author":"Hr\u00f3bjartsson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0370","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jclp.20356","article-title":"Wampold et al.'s reiterate spin in the conclusion of a re-analysis of placebo versus no-treatment trials despite similar results as in original review","volume":"63","author":"Hr\u00f3bjartsson","year":"2007","journal-title":"J Clin Psychol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0375","first-page":"CD003974","article-title":"Placebo interventions for all clinical conditions","volume":"1","author":"Hr\u00f3bjartsson","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0380","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0031-1286260","article-title":"Exploratory review of placebo characteristics reported in randomised placebo controlled antidepressant drug trials","volume":"45","author":"Hughes","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0385","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0390","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0395","doi-asserted-by":"crossref","first-page":"15959","DOI":"10.1073\/pnas.1202056109","article-title":"Nonconscious activation of placebo and nocebo pain responses","volume":"109","author":"Jensen","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0400","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/j.1460-9568.2004.03310.x","article-title":"Expectation of caffeine induces dopaminergic responses in humans","volume":"19","author":"Kaasinen","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0405","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0410","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bmj.39524.439618.25","article-title":"Components of placebo effect: randomized controlled trial in patients with irritable bowel syndrome","volume":"336","author":"Kaptchuk","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0415","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cct.2008.02.002","article-title":"Do \u201cplacebo responders\u201d exist?","volume":"29","author":"Kaptchuk","year":"2008","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0420","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1176\/appi.ajp.162.5.939","article-title":"Evidence for onset of antipsychotic effects within the first 24hours of treatment","volume":"162","author":"Kapur","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0425","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/476142a","article-title":"Why fake it? How \u201csham\u201d brain surgery could be killing off valuable therapies for Parkinson's disease","volume":"476","author":"Katsnelson","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0430","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mds.24940","article-title":"Comparison of enrollees and decliners of Parkinson disease sham surgery trials","volume":"27","author":"Kim","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0440","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1037\/0033-2909.130.2.341","article-title":"Conditioning, expectancy, and the placebo effect: comment on Stewart-Williams and Podd","volume":"130","author":"Kirsch","year":"2004","journal-title":"Psychol Bull"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0435","first-page":"2a","article-title":"Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication","volume":"1","author":"Kirsch","year":"1998","journal-title":"Prev Treat"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0445","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/YCO.0b013e3282f50c36","article-title":"Neurophysiology and psychobiology of the placebo response","volume":"21","author":"Klosterhalfen","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0450","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.tvir.2012.02.008","article-title":"Placebo power","volume":"15","author":"Knox","year":"2012","journal-title":"Tech Vasc Interv Radiol"},{"issue":"e49784","key":"10.1016\/j.pharmthera.2013.07.009_bb0455","first-page":"1","article-title":"Placebo analgesia affects brain correlates of error processing","volume":"7","author":"Koban","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0460","doi-asserted-by":"crossref","first-page":"13354","DOI":"10.1523\/JNEUROSCI.2944-08.2008","article-title":"A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect","volume":"28","author":"Kong","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0465","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.pain.2012.12.004","article-title":"Functional connectivity of the frontoparietal network predicts cognitive modulation of pain","volume":"154","author":"Kong","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0470","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.pain.2009.09.033","article-title":"Prefrontal cortex modulates placebo analgesia","volume":"148","author":"Krummenacher","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0475","series-title":"Hawthorne Revisited: Management and the Worker: Its Critics, and Developments in Human Relations in Industry","author":"Landsberger","year":"1958"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0480","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1474-4422(06)70359-3","article-title":"GDNF in treatment of Parkinson's disease: response to editorial","volume":"5","author":"Lang","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0485","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1176\/appi.ajp.159.1.122","article-title":"Changes in brain function of depressed subjects during treatment with placebo","volume":"159","author":"Leuchter","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0490","article-title":"The mechanism of placebo analgesia","volume":"654\u2013657","author":"Levine","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0495","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0505","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.spmd.2005.02.004","article-title":"The placebo response as a reward mechanism","volume":"3","author":"Lidstone","year":"2005","journal-title":"Semin Pain Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0510","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archgenpsychiatry.2010.88","article-title":"Effects of expectation on placebo-induced dopamine release in Parkinson disease","volume":"67","author":"Lidstone","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0500","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s11307-007-0086-3","article-title":"Understanding the placebo effect: contributions from neuroimaging","volume":"9","author":"Lidstone","year":"2007","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0525","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1523\/JNEUROSCI.0626-06.2006","article-title":"Blood oxygenation level-dependent visualization of synaptic relay stations of sensory pathways along the neuroaxis in response to graded sensory stimulation of a limb","volume":"26","author":"Lilja","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0530","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.pain.2010.09.021","article-title":"Neural bases of conditioned placebo analgesia","volume":"151","author":"Lui","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0535","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.pain.2011.07.010","article-title":"Variability in placebo analgesia and the role of fear of pain\u2014an ERP study","volume":"152","author":"Lyby","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0540","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.pain.2012.02.042","article-title":"Induced fear reduces the effectiveness of a placebo intervention on pain","volume":"153","author":"Lyby","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0550","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0545","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0555","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1176\/appi.ajp.159.5.728","article-title":"The functional neuroanatomy of the placebo effect","volume":"159","author":"Mayberg","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0560","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.sleep.2011.03.008","article-title":"Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs","volume":"12","author":"McCall","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0565","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archpsyc.61.4.412","article-title":"Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial","volume":"61","author":"McRae","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0570","doi-asserted-by":"crossref","first-page":"16117","DOI":"10.1523\/JNEUROSCI.4099-11.2011","article-title":"The placebo effect: advances from different methodological approaches","volume":"31","author":"Meissner","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0575","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1082-3174(96)80062-6","article-title":"Pain mechanisms: a new theory","volume":"5","author":"Melzack","year":"1965","journal-title":"Pain Forum"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0580","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/mds.20935","article-title":"Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation","volume":"21","author":"Mercado","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0585","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/0333102410391485","article-title":"Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches","volume":"31","author":"Mitsikostas","year":"2011","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0590","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pain.2009.07.026","article-title":"Reproducibility of placebo analgesia: effect of dispositional optimism","volume":"146","author":"Morton","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0595","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.pain.2012.04.026","article-title":"Placebo-induced analgesia in an operant pain model in rats","volume":"153","author":"Nolan","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0605","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1093\/brain\/awn116","article-title":"Placebo effects: clinical aspects and neurobiology","volume":"131","author":"Oken","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0600","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/WNL.53.4.679","article-title":"Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS study","volume":"53","author":"Once Weekly Interferon for MS Study Group (OWIMS)","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0610","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.bbi.2006.05.003","article-title":"Expectations and associations that heal: immunomodulatory placebo effects and its neurobiology","volume":"20","author":"Pacheco-L\u00f3pez","year":"2006","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0615","article-title":"Personality trait predictors of placebo analgesia and neurobiological correlates","volume":"1\u20138","author":"Peci\u00f1a","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0620","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/mds.22694","article-title":"Restless legs syndrome in Parkinson's disease","volume":"24","author":"Peralta","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0625","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.pain.2012.03.011","article-title":"Placebo manipulations reduce hyperalgesia in neuropathic pain","volume":"153","author":"Petersen","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0635","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.neuron.2005.05.023","article-title":"Placebo in emotional processing\u2014induced expectations of anxiety relief activate a generalized modulatory network","volume":"46","author":"Petrovic","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0640","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pain.2010.03.011","article-title":"A prefrontal non-opioid mechanism in placebo analgesia","volume":"150","author":"Petrovic","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0630","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1126\/science.1067176","article-title":"Placebo and opioid analgesia\u2014imaging a shared neuronal network","volume":"295","author":"Petrovic","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0645","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-physiol-030212-183717","article-title":"Pathophysiology of migraine","volume":"75","author":"Pietrobon","year":"2013","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0650","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0079-6123(09)17520-9","article-title":"The placebo response: neurobiological and clinical issues of neurological relevance","volume":"175","author":"Pollo","year":"2009","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0655","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1098\/rstb.2010.0381","article-title":"Placebo mechanisms across different conditions: from the clinical setting to physical performance","volume":"366","author":"Pollo","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0660","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1007\/s00421-012-2333-9","article-title":"Preventing motor training through nocebo suggestions","volume":"112","author":"Pollo","year":"2012","journal-title":"Eur J Appl Physiol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0665","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1126\/science.288.5472.1769","article-title":"Psychological and neural mechanisms of the affective dimension of pain","volume":"288","author":"Price","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0675","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.psych.59.113006.095941","article-title":"A comprehensive review of the placebo effect: recent advances and current thought","volume":"59","author":"Price","year":"2008","journal-title":"Annu Rev Psychol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0670","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3959(02)00053-2","article-title":"Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients","volume":"99","author":"Price","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0680","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0959-4388(02)00313-6","article-title":"Brain mechanisms of pain affect and pain modulation","volume":"12","author":"Rainville","year":"2002","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0685","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/11590590-000000000-00000","article-title":"Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders","volume":"50","author":"Reddy","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0690","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease","volume":"78","author":"Richard","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0700","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/clpt.2011.204","article-title":"Mechanisms involved in placebo and nocebo responses and implications for drug trials","volume":"90","author":"Rief","year":"2011","journal-title":"Nat Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0695","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.pain.2012.09.007","article-title":"The hidden effects of blinded, placebo-controlled randomized trials: an experimental investigation","volume":"153","author":"Rief","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2009.01.029","article-title":"Meta-analysis of the placebo response in antidepressant trials","volume":"118","author":"Rief","year":"2009","journal-title":"J Affect Disord"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0710","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2214.2007.00797.x","article-title":"Open-label use of placebos in the treatment of ADHD: a pilot study","volume":"34","author":"Sandler","year":"2008","journal-title":"Child Care Health Dev"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0725","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0896-6273(02)00967-4","article-title":"Getting formal with dopamine and reward","volume":"36","author":"Schultz","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0715","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1523\/JNEUROSCI.5634-08.2009","article-title":"The anatomy of the mesolimbic reward system: a link between personality and the placebo analgesic response","volume":"29","author":"Schweinhardt","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0720","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2007.34","article-title":"Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses","volume":"65","author":"Scott","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0730","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/j.pain.2012.07.010","article-title":"White matter integrity of the descending pain modulatory system is associated with interindividual differences in placebo analgesia","volume":"153","author":"Stein","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0735","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.nurt.2008.02.006","article-title":"Spheramine for treatment of Parkinson's disease","volume":"5","author":"Stover","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0750","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.neuroimage.2006.02.005","article-title":"Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation","volume":"31","author":"Strafella","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0740","doi-asserted-by":"crossref","first-page":"RC157","DOI":"10.1523\/JNEUROSCI.21-15-j0003.2001","article-title":"Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus","volume":"21","author":"Strafella","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0745","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1093\/brain\/awg268","article-title":"Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex","volume":"126","author":"Strafella","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0755","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1037\/h0071663","article-title":"A constant error in psychological ratings","volume":"4","author":"Thorndike","year":"1920","journal-title":"J Appl Psychol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0760","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/nm.2229","article-title":"Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans","volume":"16","author":"Tracey","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0765","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.evolhumbehav.2012.07.004","article-title":"Understanding the placebo effect from an evolutionary perspective","volume":"34","author":"Trimmer","year":"2012","journal-title":"Evol Hum Behav"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0770","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.pain.2005.03.014","article-title":"Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms","volume":"115","author":"Vase","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0775","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ana.410410111","article-title":"Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?","volume":"41","author":"Vingerhoets","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0780","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrn1704","article-title":"Pain and emotion interactions in subregions of the cingulate gyrus","volume":"6","author":"Vogt","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0790","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.neuroimage.2006.04.192","volume":"32","author":"Volkow","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0785","doi-asserted-by":"crossref","first-page":"11461","DOI":"10.1523\/JNEUROSCI.23-36-11461.2003","volume":"23","author":"Volkow","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0805","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1523\/JNEUROSCI.3420-10.2011","article-title":"Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain experience","volume":"31","author":"Wager","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0795","series-title":"Placebo analgesia. Ed. 6. Wall and Melzack's Textbook of Pain","author":"Wager","year":"2013"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0800","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1126\/science.1093065","article-title":"Placebo-induced changes in FMRI in the anticipation and experience of pain","volume":"303","author":"Wager","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0810","first-page":"1","article-title":"The opioid placebo analgesia is mediated exclusively through \u03bc-opioid receptor in rat","volume":"25","author":"Zhang","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2013.07.009_bb0815","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1749-6632.2009.04424.x","article-title":"Neurobiological mechanisms of placebo responses","volume":"1156","author":"Zubieta","year":"2009","journal-title":"Ann N Y Acad Sci"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:30:57Z","timestamp":1563496257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725813001551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0163725813001551"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.07.009","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}